Search

Your search keyword '"Greillier, Laurent"' showing total 592 results
Start Over Author "Greillier, Laurent"
592 results on '"Greillier, Laurent"'

101. Abstract CT104: Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety results of the INTR@PID LUNG 024 study

Author

Rolfo, Christian, primary, Greillier, Laurent, additional, Veillon, Remi, additional, Badin, Firas, additional, Ghiringhelli, Francois, additional, Isambert, Nicolas, additional, Paulus, Astrid, additional, Lambrechts, Marc, additional, Grenga, Italia, additional, You, Xiaoli, additional, Koenig, Andre, additional, and Hiret, Sandrine, additional

Published
2021
Full Text
View/download PDF

103. Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer:Results from the Phase 3 TAHOE Study

Author

Blackhall, Fiona, Jao, Kevin, Greillier, Laurent, Cho, Byoung Chul, Penkov, Konstantin, Reguart, Noemi, Majem, Margarita, Nackaerts, Kristiaan, Syrigos, Konstantinos, Hansen, Karin, Schuette, Wolfgang, Cetnar, Jeremy, Cappuzzo, Federico, Okamoto, Isamu, Erman, Mustafa, Langer, Seppo W, Kato, Terufumi, Groen, Harry, Sun, Zhaowen, Luo, Yan, Tanwani, Poonam, Caffrey, Laura, Komarnitsky, Philip, and Reinmuth, Niels

Abstract

INTRODUCTION: Delta-like protein 3 (DLL3), an atypical Notch ligand, is expressed in small cell lung cancer (SCLC) tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine via a protease-cleavable linker. Efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated.METHODS: TAHOE was an open-label, 2:1 randomized, phase 3 study comparing Rova-T with topotecan as second-line therapy in DLL3-high advanced or metastatic SCLC. Rova-T (0.3 mg/kg) was administered intravenously on Day 1 of a 42-day cycle for 2 cycles, with 2 additional cycles available to patients who met protocol-defined criteria for continued dosing. Topotecan (1.5 mg/m2) was administered intravenously on Days 1-5 of a 21-day cycle. The primary endpoint was overall survival (OS).RESULTS: Patients randomized to Rova-T (n=296) and topotecan (n=148) were included in efficacy analyses. The median age was 64 years, and 77% had extensive disease at initial diagnosis. Median OS (95% CI) was 6.3 months (5.6-7.3) in the Rova-T arm and 8.6 months (7.7, 10.1) in the topotecan arm (hazard ratio, 1.46 [95% CI: 1.17-1.82]). An independent data monitoring committee recommended that enrollment be discontinued due to shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports.CONCLUSIONS: Compared with topotecan, which is the current standard second-line chemotherapy, Rova-T showed an inferior OS and higher rates of serosal effusions, photosensitivity reaction, and peripheral edema in patients with SCLC. Significant unmet therapeutic need remains in this population.

Published
2021

104. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Author

Blackhall, Fiona Jao, Kevin Greillier, Laurent Cho, Byoung Chul Penkov, Konstantin Reguart, Noemi Majem, Margarita and Nackaerts, Kristiaan Syrigos, Konstantinos Hansen, Karin and Schuette, Wolfgang Cetnar, Jeremy Cappuzzo, Federico and Okamoto, Isamu Erman, Mustafa Langer, Seppo W. Kato, Terufumi Groen, Harry Sun, Zhaowen Luo, Yan Tanwani, Poonam Caffrey, Laura Komarnitsky, Philip Reinmuth, Niels

Abstract

Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. The efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated. Methods: The TAHOE study was an open-label, two-to-one randomized, phase 3 study comparing Rova-T with topotecan as second-line therapy in DLL3-high advanced or metastatic SCLC. Rova-T (0.3 mg/kg) was administered intravenously on day 1 of a 42-day cycle for two cycles, with two additional cycles available to patients who met protocol-defined criteria for continued dosing. Topotecan (1.5 mg/m(2)) was administered intravenously on days 1 to 5 of a 21-day cycle. The primary end point was overall survival (OS). Results: Patients randomized to Rova-T (n = 296) and topotecan (n = 148) were included in the efficacy analyses. The median age was 64 years, and 77% had the extensive disease at initial diagnosis. The median OS (95% confidence interval) was 6.3 months (5.6-7.3) in the Rova-T arm and 8.6 months (7.7-10.1) in the topotecan arm (hazard ratio, 1.46 [95% confidence interval: 1.17-1.82]). An independent data monitoring committee recommended that enrollment be discontinued because of the shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports. Conclusions: Compared with topotecan, which is the current standard second-line chemotherapy, Rova-T exhibited an inferior OS and higher rates of serosal effusions, photosensitivity reaction, and peripheral edema in patients with SCLC. A considerable unmet therapeutic need remains in this population. (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.

Published
2021

106. Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

Author

Mazieres, Julien, primary, Lafitte, Claire, additional, Ricordel, Charles, additional, Greillier, Laurent, additional, Pujol, Jean-Louis, additional, Zalcman, Gerard, additional, Domblides, Charlotte, additional, Madelaine, Jeannick, additional, Bennouna, Jaafar, additional, Mascaux, Celine, additional, Moro-Sibilot, Denis, additional, Pinquié, François, additional, Cortot, Alexis, additional, Otto, Josiane, additional, Cadranel, Jacques, additional, Langlais, Alexandra, additional, Morin, Franck, additional, Westeel, Virginie, additional, and Besse, Benjamin, additional

Published
2021
Full Text
View/download PDF

107. First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).

Author

Descourt, Renaud, primary, Greillier, Laurent, additional, Perol, Maurice, additional, Ricordel, Charles, additional, Auliac, Jean-Bernard, additional, Falchero, Lionel, additional, Demontrond, Pierre, additional, Veillon, Remi, additional, Vieillot, Sabine, additional, Guisier, Florian, additional, Marcq, Marie, additional, Justeau, Gregoire, additional, Bigay Game, Laurence, additional, Bernardi, Marie, additional, Fournel, Pierre, additional, Doubre, Helene, additional, Pinsolle, Julian, additional, Amrane, Karim, additional, Chouaid, Christos, additional, and Decroisette, Chantal, additional

Published
2021
Full Text
View/download PDF

108. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

Author

Ilié, Marius, primary, Mazières, Julien, additional, Chamorey, Emmanuel, additional, Heeke, Simon, additional, Benzaquen, Jonathan, additional, Thamphya, Brice, additional, Boutros, Jacques, additional, Tiotiu, Angélica, additional, Fayada, Julien, additional, Cadranel, Jacques, additional, Poudenx, Michel, additional, Moro-Sibilot, Denis, additional, Barlesi, Fabrice, additional, Thariat, Juliette, additional, Clément-Duchêne, Christelle, additional, Tomasini, Pascale, additional, Hofman, Véronique, additional, Marquette, Charles-Hugo, additional, Hofman, Paul, additional, Israel-Biet, Dominique, additional, Pison, Christophe, additional, Lantuejoul, Sylvie, additional, Stephanov, Olivier, additional, Juliette, Meyzenc, additional, Mendozat, Christophe, additional, Zaidi, Manel, additional, Coulouvrat, Sandra, additional, Col, Edwige, additional, Chanez, Pascal, additional, Greillier, Laurent, additional, Mascaux, Céline, additional, Jourdan, Sandrine, additional, Roger, Aurélie, additional, Biemar, Julie, additional, Randriamampionona, Rondro, additional, Chabot, François, additional, Clement-Duchene, Christelle, additional, Vignaud, Jean-Michel, additional, Lacomme, Stéphanie, additional, Lomazzi, Sandra, additional, Laurent, Carine, additional, Bulsei, Xavier, additional, Bischoff, Laura, additional, Rakotonirina, Raymond, additional, Layouni, Mehdi, additional, Deslee, Gaëtan, additional, Mal, Hervé, additional, Kessler, Romain, additional, Vergnon, Jean-Michel, additional, Pelissier, Isabelle, additional, Cuvelier, Antoine, additional, Bourdin, Arnaud, additional, Jounieaux, Vincent, additional, Roche, Nicolas, additional, Jouneau, Stéphane, additional, Bonniaud, Philippe, additional, Scherpereel, Arnaud, additional, Mornex, Jean François, additional, Steenhouwer, François, additional, Leroy, Sylvie, additional, Marquette, Charles Hugo, additional, Mazzette, Andrea, additional, Padovani, Bernard, additional, Ilié, Marius, additional, Long-Mira, Elodie, additional, Lassalle, Sandra, additional, Pradelli, Johanna, additional, Martinez, Estelle, additional, Habault, Marine, additional, Bonnard, Mélanie, additional, Moutarde, Julie, additional, Yatimi, Rachida, additional, Labsi, Hakima, additional, Gazoppi, Loïc, additional, Lpce, Tumorothèque, additional, Griffonnet, Jennifer, additional, Fontaine, Maureen, additional, Guillemart, Ariane, additional, Butori, Catherine, additional, Selva, Eric, additional, Otto, Josiane, additional, Hebert, Christophe, additional, Botchiellini, Delphine, additional, Boudouf, Soukaina, additional, Menier, Margaux, additional, Occeli, Estelle, additional, Bellentani, Sophie, additional, Pion, Carine, additional, Fournier, Elodie, additional, Gervais, Radj, additional, Hamond, Karim, additional, Marchand-Adam, Sylvain, additional, Plantier, Laurent, additional, Fajolle, Gaelle, additional, Rayez, Mélanie, additional, Fallet, Vincent, additional, Wislez, Marie, additional, Antoine, Martine, additional, Cote, Jean-François, additional, Chaabane, Nouha, additional, Ruppert, Anne Marie, additional, Bertrand, Eliane, additional, Rodenas, Anita, additional, Pontdeme, Gwenaëlle, additional, Mathiot, Nathalie, additional, Ribert, Tamazouzt, additional, Guibert, Nicolas, additional, Rouviere, Damien, additional, Bousquet, Emilie, additional, Bigay-Game, Laurence, additional, Hermant, Christophe, additional, Plat, Gavin, additional, Rouquette, Isabelle, additional, Evrard, Solène, additional, Gouin, Sandrine, additional, Clermont, Estelle Taranchon, additional, Dormoy, Inge, additional, Coulomb, Christelle, additional, Pradine, Anne, additional, Lambert, Véronique, additional, Laborde, Lilian, additional, and Castelnau, Olivier, additional

Published
2021
Full Text
View/download PDF

109. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Author

Owonikoko, Taofeek K., primary, Park, Keunchil, additional, Govindan, Ramaswamy, additional, Ready, Neal, additional, Reck, Martin, additional, Peters, Solange, additional, Dakhil, Shaker R., additional, Navarro, Alejandro, additional, Rodríguez-Cid, Jerónimo, additional, Schenker, Michael, additional, Lee, Jong-Seok, additional, Gutierrez, Vanesa, additional, Percent, Ivor, additional, Morgensztern, Daniel, additional, Barrios, Carlos H., additional, Greillier, Laurent, additional, Baka, Sofia, additional, Patel, Miten, additional, Lin, Wen Hong, additional, Selvaggi, Giovanni, additional, Baudelet, Christine, additional, Baden, Jonathan, additional, Pandya, Dimple, additional, Doshi, Parul, additional, and Kim, Hye Ryun, additional

Published
2021
Full Text
View/download PDF

114. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Author

Baas, Paul, primary, Scherpereel, Arnaud, additional, Nowak, Anna K, additional, Fujimoto, Nobukazu, additional, Peters, Solange, additional, Tsao, Anne S, additional, Mansfield, Aaron S, additional, Popat, Sanjay, additional, Jahan, Thierry, additional, Antonia, Scott, additional, Oulkhouir, Youssef, additional, Bautista, Yolanda, additional, Cornelissen, Robin, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Kowalski, Dariusz, additional, Rodríguez-Cid, Jerónimo, additional, Aanur, Praveen, additional, Oukessou, Abderrahim, additional, Baudelet, Christine, additional, and Zalcman, Gérard, additional

Published
2021
Full Text
View/download PDF

115. Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study

Author

Couderc, Anne-Laure, Boisseranc, Celia, Rey, Dominique, Nouguerede, Emilie, Greillier, Laurent, Barlesi, Fabrice, Duffaud, Florence, Deville, Laurent, Honoré, Stéphane, Villani, Patrick, Correard, Florian, Assistance Publique - Hôpitaux de Marseille (APHM), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre régional de pharmacovigilance de Marseille Provence Corse [CHU de Marseille] (CRPV-Marseille), Assistance Publique - Hôpitaux de Marseille (APHM)-CHU Marseille, and CHU Marseille-Assistance Publique-Hôpitaux de Marseille (AP-HM)

Subjects
Aged, 80 and over, Male, geriatric assessment, [SDV]Life Sciences [q-bio], [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Clinical Decision-Making, antineoplastic protocols, [SDV.CAN]Life Sciences [q-bio]/Cancer, Medical Oncology, Patient Care Planning, [SHS]Humanities and Social Sciences, [SDV.ETH]Life Sciences [q-bio]/Ethics, aged, Neoplasms, Clinical Interventions in Aging, Polypharmacy, medication reconciliation, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Humans, Female, Prospective Studies, ComputingMilieux_MISCELLANEOUS, Original Research, treatment failure
Abstract

Anne-Laure Couderc,1,2 Celia Boisseranc,3 Dominique Rey,1 Emilie Nouguerede,1 Laurent Greillier,4,5 Fabrice Barlesi,4,5 Florence Duffaud,4,6 Jean-Laurent Deville,6 Stéphane Honoré,3,4 Patrick Villani,1,2 Florian Correard3,4 1Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille, France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille, France; 2Aix-Marseille Université, CNRS, EFS, ADES, Marseille, France; 3Pharmacology Department, AP-HM, Marseille, France; 4Aix-Marseille University, Marseille, France; 5Multidisciplinary Oncology and Therapeutic Innovations Unit, AP-HM, Marseille, France; 6Oncology Unit, AP-HM, Marseille, FranceCorrespondence: Anne-Laure CoudercCoordination Unit for Geriatric Oncology (UCOG), PACA West, University Hospital of Marseille (AP-HM), 270 Boulevard De Sainte Marguerite, Marseille 13009, FranceTel +33 491744530Fax +33 491744833Email anne-laure.couderc@ap-hm.frBackground: Polymorbidity induces polypharmacy in older patients may lead to potential drug–drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment.Methods: ChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment.Results: One hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities – irrespective of grade and type – than patients who received standard treatment (p< 0.001) and had comparable overall survival (Log rank p=0.21).Conclusion: This is one of the first studies to highlight the value in conducting CMR and a CGA simultaneously before initiating systemic treatment in older patients with cancer. These two evaluations could give oncologists decisive information to personalize cancer treatment of older patients and optimize treatment dose to offer the best efficacy and minimize toxicity.Keywords: aged, antineoplastic protocols, geriatric assessment, medication reconciliation, treatment failure

Published
2020

117. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Author

Dingemans, Anne-Marie C, Hendriks, Lizza E L, Berghmans, Thierry, Levy, Antonin, Hasan, Baktiar, Faivre-Finn, Corinne, Giaj-Levra, Matteo, Giaj-Levra, Niccolò, Girard, Nicolas, Greillier, Laurent, Lantuéjoul, Sylvie, Edwards, John, O’Brien, Mary, Reck, Martin, Smit, Egbert F, Van Schil, Paul, Postmus, Pieter E, Ramella, Sara, Lievens, Yolande, Gaga, Mina, Peled, Nir, Scagliotti, Giorgio V, Senan, Suresh, Paz-Ares, Luiz, Guckenberger, Matthias, McDonald, Fiona, Ekman, Simon, Cufer, Tanja, Gietema, Hester, Infante, Maurizio, et al, University of Zurich, and Dingemans, Anne-Marie C

Subjects
Pulmonary and Respiratory Medicine, Oncology, 2740 Pulmonary and Respiratory Medicine, 610 Medicine & health, 2730 Oncology, 10044 Clinic for Radiation Oncology
Published
2019

118. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Author

Herbreteau, Guillaume, primary, Langlais, Alexandra, additional, Greillier, Laurent, additional, Audigier-Valette, Clarisse, additional, Uwer, Lionel, additional, Hureaux, José, additional, Moro-Sibilot, Denis, additional, Guisier, Florian, additional, Carmier, Delphine, additional, Madelaine, Jeannick, additional, Otto, Josiane, additional, Souquet, Pierre-Jean, additional, Gounant, Valérie, additional, Merle, Patrick, additional, Molinier, Olivier, additional, Renault, Aldo, additional, Rabeau, Audrey, additional, Morin, Franck, additional, Denis, Marc G, additional, and Pujol, Jean-Louis, additional

Published
2020
Full Text
View/download PDF

120. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.

Author

Mazieres, Julien, Lafitte, Claire, Ricordel, Charles, Greillier, Laurent, Negre, Elodie, Zalcman, Gérard, Domblides, Charlotte, Madelaine, Jeannick, Bennouna, Jaafar, Mascaux, Céline, Moro-Sibilot, Denis, Pinquie, François, Cortot, Alexis B, Otto, Josiane, Cadranel, Jacques, Langlais, Alexandra, Morin, Franck, Westeel, Virginie, and Besse, Benjamin

Published
2022
Full Text
View/download PDF

124. High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer

Author

Couderc, Anne-Laure, primary, Puchades, Eddy, additional, Villani, Patrick, additional, Arcani, Robin, additional, Farnault, Laure, additional, Daumas, Aurélie, additional, Courcier, Anais, additional, Greillier, Laurent, additional, Barlesi, Fabrice, additional, Duffaud, Florence, additional, Salas, Sébastien, additional, Costello, Régis, additional, Gentile, Gaëtan, additional, Pradel, Vincent, additional, Suchon, Pierre, additional, and Venton, Geoffroy, additional

Published
2020
Full Text
View/download PDF

125. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Author

Opitz, Isabelle, primary, Scherpereel, Arnaud, additional, Berghmans, Thierry, additional, Psallidas, Ioannis, additional, Glatzer, Markus, additional, Rigau, David, additional, Astoul, Philippe, additional, Bölükbas, Servet, additional, Boyd, Jeanette, additional, Coolen, Johan, additional, De Bondt, Charlotte, additional, De Ruysscher, Dirk, additional, Durieux, Valerie, additional, Faivre-Finn, Corinne, additional, Fennell, Dean A, additional, Galateau-Salle, Francoise, additional, Greillier, Laurent, additional, Hoda, Mir Ali, additional, Klepetko, Walter, additional, Lacourt, Aude, additional, McElnay, Phil, additional, Maskell, Nick A, additional, Mutti, Luciano, additional, Pairon, Jean-Claude, additional, Van Schil, Paul, additional, van Meerbeeck, Jan P, additional, Waller, David, additional, Weder, Walter, additional, Putora, Paul Martin, additional, and Cardillo, Giuseppe, additional

Published
2020
Full Text
View/download PDF

126. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Author

Scherpereel, Arnaud, primary, Opitz, Isabelle, additional, Berghmans, Thierry, additional, Psallidas, Ioannis, additional, Glatzer, Markus, additional, Rigau, David, additional, Astoul, Philippe, additional, Bölükbas, Servet, additional, Boyd, Jeanette, additional, Coolen, Johan, additional, De Bondt, Charlotte, additional, De Ruysscher, Dirk, additional, Durieux, Valerie, additional, Faivre-Finn, Corinne, additional, Fennell, Dean, additional, Galateau-Salle, Francoise, additional, Greillier, Laurent, additional, Hoda, Mir Ali, additional, Klepetko, Walter, additional, Lacourt, Aude, additional, McElnay, Phil, additional, Maskell, Nick A., additional, Mutti, Luciano, additional, Pairon, Jean-Claude, additional, Van Schil, Paul, additional, van Meerbeeck, Jan P., additional, Waller, David, additional, Weder, Walter, additional, Cardillo, Giuseppe, additional, and Putora, Paul Martin, additional

Published
2020
Full Text
View/download PDF

127. First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial

Author

Lavole, Armelle, primary, Greillier, Laurent, additional, Mazières, Julien, additional, Monnet, Isabelle, additional, Kiakouama-Maleka, Lize, additional, Quantin, Xavier, additional, Spano, Jean Philippe, additional, Herve, Lena, additional, Fraisse, Philippe, additional, Janicot, Henri, additional, Audigier-Valette, Clarisse, additional, Langlais, Alexandra, additional, Morin, Franck, additional, Makinson, Alain, additional, and Cadranel, Jacques, additional

Published
2020
Full Text
View/download PDF

128. Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.

Author

Girard, Nicolas, primary, Petat, Arthur, additional, Dansin, Eric, additional, Fabien, Calcagno, additional, Greillier, Laurent, additional, Pichon, Eric, additional, Kerjouan, Mallorie, additional, Clément Duchene, Christelle, additional, Mennecier, Bertrand, additional, Westeel, Virginie, additional, Thillays, Francois, additional, Quantin, Xavier, additional, Ginoux, Marylise, additional, Oulkhouir, Youssef, additional, Thiberville, Luc, additional, Ricordel, Charles, additional, Molina, Thierry, additional, Fournel, Pierre, additional, Bigay-Game, Laurence, additional, and Besse, Benjamin, additional

Published
2020
Full Text
View/download PDF

129. Development and Validation of a Simplified Prognostic Score in SCLC

Author

Negre, Elodie, primary, Coffy, Amandine, additional, Langlais, Alexandra, additional, Daures, Jean-Pierre, additional, Lavole, Armelle, additional, Quoix, Elisabeth, additional, Molinier, Olivier, additional, Greillier, Laurent, additional, Audigier-Valette, Clarisse, additional, Moro-Sibilot, Denis, additional, Westeel, Virginie, additional, Morin, Franck, additional, Roch, Benoît, additional, and Pujol, Jean-Louis, additional

Published
2020
Full Text
View/download PDF

131. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Author

Morgensztern, Daniel, primary, Besse, Benjamin, additional, Greillier, Laurent, additional, Santana-Davila, Rafael, additional, Ready, Neal, additional, Hann, Christine L., additional, Glisson, Bonnie S., additional, Farago, Anna F., additional, Dowlati, Afshin, additional, Rudin, Charles M., additional, Le Moulec, Sylvestre, additional, Lally, Satwant, additional, Yalamanchili, Sreeni, additional, Wolf, Jürgen, additional, Govindan, Ramaswamy, additional, and Carbone, David P., additional

Published
2019
Full Text
View/download PDF

133. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

Author

Levy, Antonin, primary, Hendriks, Lizza E.L., additional, Berghmans, Thierry, additional, Faivre-Finn, Corinne, additional, GiajLevra, Matteo, additional, GiajLevra, Niccolò, additional, Hasan, Baktiar, additional, Pochesci, Alessia, additional, Girard, Nicolas, additional, Greillier, Laurent, additional, Lantuéjoul, Sylvie, additional, Edwards, John, additional, O'Brien, Mary, additional, Reck, Martin, additional, Besse, Benjamin, additional, Novello, Silvia, additional, and Dingemans, Anne-Marie C., additional

Published
2019
Full Text
View/download PDF

135. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

Author

Eberst, Guillaume, primary, Anota, Amélie, additional, Scherpereel, Arnaud, additional, Mazieres, Julien, additional, Margery, Jacques, additional, Greillier, Laurent, additional, Audigier-Valette, Clarisse, additional, Moro-Sibilot, Denis, additional, Molinier, Olivier, additional, Léna, Hervé, additional, Rivière, Frédéric, additional, Monnet, Isabelle, additional, Gounant, Valérie, additional, Janicot, Henri, additional, Gervais, Radj, additional, Locher, Chrystelle, additional, Charton, Emilie, additional, Morin, Franck, additional, Zalcman, Gérard, additional, and Westeel, Virginie, additional

Published
2019
Full Text
View/download PDF

142. Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.

Author

Monnet, Isabelle, Vergnenègre, Alain, Robinet, Gilles, Berard, Henri, Lamy, Regine, Falchero, Lionel, Vieillot, Sabine, Schott, Roland, Ricordel, Charles, Chouabe, Stephane, Thomas, Pascal, Gervais, Radj, Madroszyk, Anne, Abdiche, Samir, Chiappa, Anne Marie, Greillier, Laurent, Decroisette, Chantal, Auliac, Jean Bernard., and Chouaïd, Christos

Abstract

Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring BR until cerebral progression was superior to upfront BR for patients with aNSCLC and aBM. Methods: This open-label, multicenter, phase III trial, randomized (1:1) aNSCLC patients with aBMs to receive upfront BR and chemotherapy: platin–pemetrexed and bevacizumab in eligible patients, followed by maintenance pemetrexed with or without bevacizumab, BR arm, or the same chemotherapy with BR only at cerebral progression, chemotherapy (ChT) arm. Primary endpoint was progression-free survival (PFS), secondary endpoints were overall survival (OS), global, extra-cerebral and cerebral objective response rate (ORR), toxicity, and quality of life [ClinicalTrials.gov identifier: NCT02162537]. Results: The trial was stopped early because of slow recruitment. Among 95 included patients, 91 were randomized in 24 centers: 45 to BR and 46 to ChT arms (age: 60 ± 8.1, men: 79%, PS 0/1: 51.7%/48.3%; adenocarcinomas: 92.2%, extra-cerebral metastases: 57.8%, without differences between arms.) Significantly more patients in the BR-arm received BR compare with those in the ChT arm (87% versus 20%; p < 0.001); there were no significant differences between BR and ChT arms for median PFS: 4.7, 95% confidence interval (CI):3.4–7.5 versus 4.8, 95% CI: 2.4–6.5 months, for median OS: 8.5, 95% CI:.6–11.1 versus 8.3, 95% CI:4.5–11.5 months, cerebral and extra-cerebral ORR (27% versus 13%, p = 0.064, and 30% versus 41%, p = 0.245, respectively). The ChT arm had more grade 3/4 neutropenia than the BR arm (13% versus 6%, p = 0.045); others toxicities were comparable. Conclusion: The significant BR rate difference between the two arms suggests that upfront BR is not mandatory in aNSCLC with aBM but this trial failed to show that deferring BR for aBM is superior in terms of PFS from upfront BR. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

143. Decline in compliance to breast cancer screening in France: Results of the 5th EDIFICE survey

Author

Morere, Jean Francois, Eisinger, Francois, Blay, Jean-Yves, Greillier, Laurent, Brignoli-Guibaudet, Lysel, Lhomel, Christine, Cortot, Alexis B., Couraud, Sebastien, Viguier, Jerome, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and DUFOUR, Jean-Charles

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 05-09, 2017

Published
2018

144. Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Author

Malhotra, Jyoti, primary, Nikolinakos, Petros, additional, Leal, Ticiana, additional, Lehman, Jonathan, additional, Morgensztern, Daniel, additional, Patel, Jyoti D., additional, Wrangle, John M., additional, Curigliano, Giuseppe, additional, Dansin, Eric, additional, Greillier, Laurent, additional, Johnson, Melissa Lynne, additional, Ready, Neal, additional, Robinet, Gilles, additional, Lally, Satwant, additional, Wong, Shekman, additional, Avsar, Emin, additional, Valenzuela, Ricardo, additional, Scripture, Charity D., additional, Selvaggi, Giovanni, additional, and Besse, Benjamin, additional

Published
2019
Full Text
View/download PDF

147. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Author

Scherpereel, Arnaud, primary, Mazieres, Julien, additional, Greillier, Laurent, additional, Lantuejoul, Sylvie, additional, Dô, Pascal, additional, Bylicki, Olivier, additional, Monnet, Isabelle, additional, Corre, Romain, additional, Audigier-Valette, Clarisse, additional, Locatelli-Sanchez, Myriam, additional, Molinier, Olivier, additional, Guisier, Florian, additional, Urban, Thierry, additional, Ligeza-Poisson, Catherine, additional, Planchard, David, additional, Amour, Elodie, additional, Morin, Franck, additional, Moro-Sibilot, Denis, additional, Zalcman, Gérard, additional, DEBIEUVRE, Didier, additional, HIRET, Sandrine, additional, CADRANEL, Jacques, additional, FRABOULET-MOREAU, Séverine, additional, and CARMIER, Delphine, additional

Published
2019
Full Text
View/download PDF

148. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Author

Auliac, Jean Bernard, primary, Pérol, Maurice, additional, Planchard, David, additional, Monnet, Isabelle, additional, Wislez, Marie, additional, Doubre, Hélène, additional, Guisier, Florian, additional, Pichon, Eric, additional, Greillier, Laurent, additional, Mastroianni, Bénédicte, additional, Decroisette, Chantal, additional, Schott, Roland, additional, Le Moulec, Sylvestre, additional, Arrondeau, Jennifer, additional, Cortot, Alexis B., additional, Gerinière, Laurence, additional, Renault, Aldo, additional, Daniel, Catherine, additional, Falchero, Lionel, additional, and Chouaid, Christos, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results